Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives

Lin, Bo; Ma, Yingyu; Wang, Junwei

doi:10.3389/fbioe.2022.870049

Cited by 14 publications

(8 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the application of nanomedicines is gradually emerging in the treatment of renal diseases. Owing to the superior targetability and improved pharmacokinetic properties of nanomedicine, kidney-targeted nanomedicine carrying drug candidates can help to address the challenges associated with DN pharmacotherapy ( 251 ).…”

Section: Clinical and Pre-clinical Therapies Targeting The Immune Sys...mentioning

confidence: 99%

“…Numerous nanomedicine-based drug delivery systems have been developed to deliver therapeutic agents specifically to the kidney ( 252 ). For example, drug nanocomplexes containing low-molecular-weight chitosan bind the megalin-cubilin receptor in proximal tubules ( 251 ). Albumin nanoparticles with specific size target mesangial cells.…”

Section: Clinical and Pre-clinical Therapies Targeting The Immune Sys...mentioning

confidence: 99%

See 1 more Smart Citation

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Liu

2022

Front. Immunol.

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is a chronic, inflammatory disease affecting millions of diabetic patients worldwide. DN is associated with proteinuria and progressive slowing of glomerular filtration, which often leads to end-stage kidney diseases. Due to the complexity of this metabolic disorder and lack of clarity about its pathogenesis, it is often more difficult to diagnose and treat than other kidney diseases. Recent studies have highlighted that the immune system can inadvertently contribute to DN pathogenesis. Cells involved in innate and adaptive immune responses can target the kidney due to increased expression of immune-related localization factors. Immune cells then activate a pro-inflammatory response involving the release of autocrine and paracrine factors, which further amplify inflammation and damage the kidney. Consequently, strategies to treat DN by targeting the immune responses are currently under study. In light of the steady rise in DN incidence, this timely review summarizes the latest findings about the role of the immune system in the pathogenesis of DN and discusses promising preclinical and clinical therapies.

show abstract

Section: Clinical and Pre-clinical Therapies Targeting The Immune Sys...mentioning

confidence: 99%

Section: Clinical and Pre-clinical Therapies Targeting The Immune Sys...mentioning

confidence: 99%

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Liu

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Transported drugs pass through the immune clearance system, thus eliminating unwanted off-target effects and improving treatment effects. 22 , 23 Therefore, the development of nanoparticle-mediated treatments is urgently required to overcome the adverse effects of conventional drug delivery methods. The current status of research and development in DN treatment is introduced and described in Table 1 .…”

Section: Introductionsmentioning

confidence: 99%

“…20 With developments in nanotechnology and biochemistry, a nanoplatform drug delivery system can be built in which anti-diabetic medicine can be broken down, implanted, encapsulated, or attached to nanoparticles. 21,22 In addition, nanoparticles modified by active targeting molecules can also contribute to efficient drug delivery. Transported drugs pass through the immune clearance system, thus eliminating unwanted off-target effects and improving treatment effects.…”

mentioning

confidence: 99%

Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy

Liu¹,

Wu²,

Gao³

et al. 2022

DMSO

View full text Add to dashboard Cite

Diabetic nephropathy (DN), a severe microvascular complication of diabetes mellitus (DM), is the most common form of chronic kidney disease (CKD) and a leading cause of renal failure in end-stage renal disease. No currently available treatment can achieve complete cure. Traditional treatments have many limitations, such as painful subcutaneous insulin injections, nephrotoxicity and hepatotoxicity with oral medication, and poor patient compliance with continual medication intake. Given the known drawbacks, recent research has suggested that nanoparticle-based drug delivery platforms as therapeutics may provide a promising strategy for treating debilitating diseases such as DN in the future. This administration method provides multiple advantages, such as delivering the loaded drug to the precise target of action and enabling early prevention of CKD progression. This article discusses the development of the main currently used nanoplatforms, such as liposomes, polymeric NPs, and inorganic NPs, as well as the prospects and drawbacks of nanoplatform application in the treatment of CKD.

show abstract

“…In this regard, nanotechnology provides a new platform for delivering drugs to treat different types of diseases including nephropathologies [ 36 , 37 ]. In particular, it can enhance renal targeting, retention, and localization [ 38 , 39 ].…”

Section: Introductionmentioning

confidence: 99%

2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis

Al-Rabia

Alfaleh²,

Asfour³

et al. 2022

Antioxidants

View full text Add to dashboard Cite

The immunosuppressant cyclosporine A (CSA) has been linked to serious renal toxic effects. Although 2-methoxyestradiol (2ME) possesses a wide range of pharmacological abilities, it suffers poor bioavailability after oral administration. The purpose of this study was to evaluate the potential of 2ME loaded D-ɑ-tocopheryl polyethylene glycol succinate (TPGS) micelles to prevent CSA-induced nephrotoxicity in rats. A 2ME-TPGS was prepared and showed particle size of 44.3 ± 3.5 nm with good entrapment efficiency and spherical structures. Male Wistar rats were divided into 5 groups, namely: Control, Vehicle, CSA, CSA + 2ME-Raw, and CSA + 2ME-Nano. CSA was injected daily at a SC dose of 20 mg/kg. Both 2ME-Raw and 2ME-Nano were given daily at oral doses of 5 mg/kg. Treatments continued for three successive weeks. 2ME-TPGS exerted significant protective effects against CSA nephrotoxicity. This was evidenced in ameliorating deterioration of renal functions, attenuation of pathological changes in kidney tissues, exerting significant anti-fibrotic, antioxidant, and anti-inflammatory effects together with significant anti-apoptotic effects. Western blot analyses showed both 2ME-Raw and 2ME-Nano significantly inhibited protein expression of TGF-β1 and phospho-ERK (p-ERK). It was observed that 2ME-TPGS, in almost all experiments, exerted superior protective effects as compared with 2ME-Raw. In conclusion, 2ME loaded in a TPGS nanocarrier possesses significant protective activities against CSA-induced kidney injury in rats. This is attributable to 2ME anti-fibrotic, antioxidant, anti-inflammatory, and anti-apoptotic activities which are mediated at least partly by inhibition of TGF-β1/p-ERK axis.

show abstract

Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives

Cited by 14 publications

References 115 publications

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy

2-Methoxyestradiol TPGS Micelles Attenuate Cyclosporine A-Induced Nephrotoxicity in Rats through Inhibition of TGF-β1 and p-ERK1/2 Axis

Contact Info

Product

Resources

About